Key result
Capecitabine-induced hand-foot syndrome affected 54.8% of patients, with female sex (aOR 0.224) and 4-6 chemotherapy cycles (aOR 0.359) independently predicting lower risk.
Cross-Sectional (n=135)
No
Capecitabine-induced hand-foot syndrome affects over half of Sudanese cancer patients on monotherapy, with female sex and 4-6 treatment cycles inversely associated with its development after adjustment.
Routine HFS monitoring remains essential for capecitabine users; this observational data extends mixed prior evidence but should not change practice.
Capecitabine-induced HFS affects more than half of patients and generally occurs early in onset. After adjustment, female patients and those who received 4-6 chemotherapy cycles were less likely to experience HFS, whereas the absence of concomitant diseases was associated with a greater likelihood of developing HFS. Early monitoring and proactive supportive care remain essential to optimize treatment continuity.
No takes yet. Share an insight, caveat, or question.
Obeid et al. (2026) conducted a cross-sectional in Cancer (n=135). Capecitabine was evaluated on Prevalence of capecitabine-induced hand-foot syndrome. Capecitabine-induced hand-foot syndrome affected 54.8% of patients, with female sex (aOR 0.224) and 4-6 chemotherapy cycles (aOR 0.359) independently predicting lower risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: